Core Viewpoint - The completion of the acquisition of 100% equity in Singapore's Dazhongtang marks a significant step for the company towards large-scale overseas expansion, with plans to increase the number of clinics in Singapore and enter markets like Hong Kong and Malaysia [1][2]. Group 1: Acquisition and Expansion Plans - The company has acquired 14 traditional Chinese medicine clinics in Singapore, covering key business districts and residential areas [2]. - The revenue of Dazhongtang in 2024 was approximately 8 million Singapore dollars (around 50 million RMB), with a growth rate exceeding 5% in 2025 [2]. - The company aims to acquire an additional 10-20 clinics in Singapore and become the leading TCM service brand in the region by 2026 [2]. Group 2: Domestic Market and Policy Environment - The domestic policy environment is stabilizing, which is favorable for leading companies in the industry [2]. - In Wuxi, the company's store revenue increased by over 40% year-on-year in October 2025, with a profit margin of 26%, significantly above the company average [2]. - The optimization of traditional Chinese medicine decoction pieces procurement rules allows the company to enjoy favorable pricing without participating in collective procurement [2]. Group 3: Shareholder Returns and Financial Outlook - The company has repurchased shares worth 232 million HKD from July 1 to November 17, 2025, significantly exceeding the 85 million HKD repurchase in the first half of the year [3]. - The management has committed to maintaining a 50% dividend payout ratio, reflecting confidence in the company's growth [3]. - The adjusted revenue growth forecasts for 2025E, 2026E, and 2027E are 11.3%, 21.9%, and 24.0%, respectively, with adjusted net profit growth of 11.9%, 23.8%, and 26.3% [3].

Core Insights - Gushengtang reported a total of 1.607 million patient visits in Q3 2025, representing a year-on-year growth of approximately 8.2% [1] - The company is expanding its domestic and international operations, aiming for a dual strategy of deep penetration in key domestic cities and accelerated overseas expansion [1] Domestic Expansion - The total number of branches will increase to 87, with four new branches added since July 2025: Shenzhen Tianyuan Hospital, Tianjin Hexi Branch, Fuzhou Taijiang Branch, and Nanjing Gulou Branch [1] - The company has successfully entered three new cities: Tianjin, Chengdu, and Shantou, while enhancing its presence in key cities like Fuzhou, Shenzhen, and Nanjing [1] International Expansion - A strategic partnership with 1doc in Singapore aims to introduce a "New Traditional Chinese Medicine" service model, integrating TCM services into existing Western medicine clinics [2] - Gushengtang will hold a 70% stake in the joint venture, with 1doc holding 30%, focusing on a collaborative approach to TCM [2] - A partnership with August Global Partners (AGP) will provide direct investment to support Gushengtang's international strategy and AI technology development [3] Acquisition Plans - Gushengtang plans to acquire 100% of DA ZHONG TANG PTE. LTD., which operates 14 TCM clinics in Singapore, enhancing its operational footprint [4] - The acquisition will integrate DA ZHONG TANG's financial performance into Gushengtang's consolidated financial statements, strengthening overall revenue [4] Share Buyback and Financial Performance - The company has repurchased a total of 11.0526 million shares for approximately HKD 339 million, with a buyback price averaging HKD 30.66 [5] - In October 2025, the company repurchased about 4.2176 million shares for HKD 127 million, and has plans for additional buybacks to enhance shareholder value [5] Financial Projections - Revenue projections for 2025-2027 are estimated at CNY 3.405 billion, CNY 4.014 billion, and CNY 4.826 billion, with net profits of CNY 406 million, CNY 533 million, and CNY 677 million respectively [6] - The projected PE ratios for the respective years are 15.8X, 12.1X, and 9.5X, maintaining a "Buy" rating [6]

Industry Insights - The domestic demand for cranes in the Chinese engineering machinery industry continues to recover, with sales of truck-mounted cranes and crawler cranes increasing by 42% and 54% year-on-year in October, respectively, driven by energy projects and wind power installations [2] - Exports of various types of engineering machinery also performed strongly in October, except for aerial work platforms and truck-mounted cranes, confirming the previous view that non-earthmoving machinery demand is recovering and will act as a catalyst for the industry [2] - The report maintains a "Buy" rating for companies such as Zoomlion (1157 HK / 000157 CH), Sany Heavy Industry (600031 CH), and Hengli Hydraulic (601100 CH), while adopting a cautious stance on Zhejiang Dingli (603338 CH) due to the continued weakness in aerial work platform sales, which fell by 39% year-on-year in October [2] Company Insights - Pinduoduo (PDD US) reported a 9.0% year-on-year revenue growth in Q3 2025, reaching 108.3 billion RMB, slightly above Bloomberg consensus expectations, primarily driven by a 7% increase in transaction service fees [6] - Baidu (BIDU US) reported a core revenue of 24.7 billion RMB in Q3 2025, a 7.0% year-on-year decline, but slightly above market expectations, with non-GAAP operating profit showing a 67% year-on-year decline [7] - Trip.com Group (TCOM US) achieved a total revenue of 18.4 billion RMB in Q3 2025, a 15.5% year-on-year increase, exceeding both internal and market expectations, driven by strong operational leverage [8] - BOSS Zhipin (BZ US) reported a 13% year-on-year revenue growth to 2.16 billion RMB in Q3 2025, with non-GAAP net profit increasing by 34% to 999.2 million RMB, benefiting from effective control of sales and R&D expenses [10] - Xiaomi Group (1810 HK) saw a 22% year-on-year revenue growth in Q3 2025, driven by the rapidly growing smart electric vehicle business and resilient internet segment, despite pressures from rising memory costs [11] - Luckin Coffee (LKNCY US) anticipates continued revenue growth in FY26, driven by store expansion and new product strategies, despite a cautious outlook on same-store sales growth due to high base effects [12][13] - Guosheng Tang (2273 HK) is entering a phase of overseas expansion with the acquisition of a 100% stake in a Singapore-based TCM clinic, aiming for significant revenue growth in the overseas market by 2026 [17][18]

Investment Rating - The report maintains a "Buy" rating for the company [7][3][8] Core Views - The company has completed the acquisition of 100% of the shares of a Singapore-based TCM clinic, marking the beginning of its overseas expansion [7][8] - The company plans to increase its store count in Singapore and expand into markets such as Hong Kong and Malaysia, with expected overseas revenue of 200-300 million RMB by 2026 [7][8] - The domestic policy environment is stabilizing, which is expected to benefit leading companies in the sector [7][8] - The management's confidence is reflected in significant share buybacks and a commitment to maintain a 50% dividend payout ratio [7][8] Financial Summary - Sales revenue is projected to grow from 3,022 million RMB in FY24 to 4,099 million RMB in FY26, representing a growth rate of 30.1% and 21.9% respectively [2][12] - Adjusted net profit is expected to increase from 400 million RMB in FY24 to 555 million RMB in FY26, with growth rates of 31.4% and 23.8% respectively [2][12] - The adjusted earnings per share (EPS) is forecasted to rise from 1.64 RMB in FY24 to 2.40 RMB in FY26 [2][12] Valuation - The target price is set at 44.95 HKD, with a potential upside of 50.3% from the current price of 29.90 HKD [3][7] - The adjusted price-to-earnings (PE) ratio for FY26 is estimated at 11.5x [7][10] Shareholder Structure - The largest shareholder holds 35.1% of the company, indicating a concentrated ownership structure [4]

晨会速递 分析师点评 市场数据 总量研究 【宏观】美国政府重新开门，市场为何"不买账"？——解构美国系列第十五篇 美国政府开门后，为何市场未定价利好，波动不止？一是停摆"不确定"，本次开门 未解决两党医保分歧，若 12 月延长医保补贴未通过，不排除民主党再度以停摆威胁 共和党让步，明年 1 月政府或再次停摆。二是降息"不确定"，尽管政府开门后经济 数据陆续发布，但 9 月非农数据时效性不足，10 月经济数据或缺失，参考价值不足， 美联储 12 月降息与否将更多依赖 12 月 5 日公布的 11 月非农数据。 行业研究 【钢铁】取向硅钢现货价格年内跌幅达到 23%——金属周期品高频数据周报 （2025.11.10-11.16）（增持） 2025 年 11 月 19 日 投资建议：2025 年 2 月 8 日，工信部出台《钢铁行业规范条件（2025 年版）》，且 7 月 18 日再次提及"推动落后产能有序退出"，我们认为钢铁板块的盈利有望修复 到历史均值水平，钢铁股的 PB 也有望随之修复。但建议防范期货价格大幅波动风险。 风险提示：根据历史数据得出的相关性失效的风险；政府对大宗商品价格调控的风险； 公司经营不善 ...

Group 1: Steel Industry - The price of oriented silicon steel has decreased by 23% year-to-date, indicating a significant drop in the metal cycle products market [4] - The Ministry of Industry and Information Technology issued the "Steel Industry Normative Conditions (2025 Edition)" on February 8, 2025, and reiterated on July 18 the need to "promote the orderly exit of backward production capacity," suggesting potential recovery in steel sector profitability to historical average levels [4] Group 2: Nuclear Fusion Industry - Fusion New Energy has announced procurement projects exceeding 2 billion yuan, focusing on power systems, low-temperature systems, and shielding layers, indicating a speeding up of industry tenders [5] - The "14th Five-Year Plan" includes nuclear fusion energy as a future industry, highlighting the long-term growth potential of the controllable nuclear fusion sector [5] Group 3: Gushengtang (2273.HK) - Gushengtang Singapore, a subsidiary of the company, has entered into a share transfer agreement to acquire 100% equity and all related rights of Da Zhong Tang PTE. LTD. as of November 16, 2025 [6] - The company's board has resolved to exercise its buyback authorization, planning to increase the buyback amount by up to 300 million HKD, demonstrating confidence in its development [6]

Core Viewpoint - The company is accelerating its overseas expansion through acquisitions, with a recent agreement to acquire 100% of Da Zhong Tang in Singapore, marking a significant step in its strategy to internationalize traditional Chinese medicine [4][5]. Group 1: Acquisition and Expansion - The company announced the acquisition of Da Zhong Tang, which operates 14 traditional Chinese medicine clinics in Singapore, enhancing its local service capabilities and user trust [4][5]. - This acquisition follows a strategic partnership with a digital healthcare platform, indicating a robust approach to expanding its market presence in Singapore through a combination of acquisitions, partnerships, and self-built initiatives [5]. Group 2: AI Development in Traditional Medicine - The company is developing AI representations of renowned doctors, leveraging extensive clinical data to replicate expert diagnostic capabilities and enhance patient care [6]. - The AI system, based on deep learning algorithms, aims to facilitate knowledge transfer from top experts to junior doctors, thereby improving the efficiency of medical resource allocation and accelerating revenue growth [6].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company is accelerating its overseas mergers and acquisitions, with a recent agreement to acquire 100% equity of Da Zhong Tang in Singapore, which operates 14 TCM clinics [1][2] - The company is also increasing its share buyback program, indicating strong confidence in future growth [1][3] - The acquisition of Da Zhong Tang will enhance the company's operational network in Singapore, supporting its international expansion strategy [2] - The company is leveraging AI technology to create "AI avatars" of renowned TCM doctors, which is expected to improve service delivery and expand capacity [3] - The company forecasts adjusted net profits of 493 million, 594 million, and 708 million HKD for 2025, 2026, and 2027 respectively, reflecting a strong growth trajectory [3] Summary by Sections Mergers and Acquisitions - The company is actively pursuing international expansion through acquisitions, with the recent purchase of Da Zhong Tang marking a significant step in its TCM overseas strategy [1][2] AI Development - The company is developing AI models based on extensive clinical data to replicate the diagnostic capabilities of top TCM experts, which is anticipated to enhance healthcare delivery [3] Financial Projections - The company projects substantial revenue growth, with expected revenues of 3,797 million, 4,735 million, and 5,902 million HKD for 2025, 2026, and 2027 respectively, alongside increasing net profits [8][9]

Summary of Guoshengtang Conference Call Company Overview - **Company**: Guoshengtang - **Industry**: Traditional Chinese Medicine (TCM) - **Key Financials**: - 2024 revenue approximately SGD 8 million - 2025 revenue growth exceeding 100% [2][3] Core Insights and Arguments - **Market Expansion**: - Active overseas market expansion through mergers, partnerships, and self-built initiatives [2][3] - Acquisition of OneDox to integrate TCM with Western medicine [2][3] - Acquisition of Dazhongtang, a leading TCM chain in Singapore, enhancing market control [2][3] - Plans to enter Hong Kong and Malaysia by 2026, with an expected addition of 20 clinics in Hong Kong [2][7] - **Financial Performance**: - Singapore's first store monthly revenue reached SGD 160,000 to 170,000, with a patient return rate exceeding 40% [2][5] - Wuxi region reported over 40% revenue growth under strict healthcare policies, with a profit margin of approximately 26% [2][5] - Strong cash flow and a short payback period for acquisitions, with a commitment to maintain a 50% dividend payout ratio [3][23] - **AI Integration**: - AI tools significantly enhance overseas operations by improving prescription accuracy and reducing training costs [3][13] - The launch of AI products has led to over 30% monthly growth in service volume and revenue [3][14] Additional Important Points - **Talent Strategy**: - Deployment of top Chinese talent to oversee local operations in overseas markets [8][19] - Focus on building localized teams to enhance operational efficiency [8] - **Payment Systems and Future Revenue**: - Current reliance on out-of-pocket payments in Singapore, with potential inclusion in future healthcare systems [9][10] - Anticipated overseas revenue to reach several hundred million RMB by 2026 [10] - **Regulatory Environment**: - Strict regulations have created opportunities for compliant companies like Guoshengtang, evidenced by growth in regions like Wuxi [22] - **Shareholder Returns**: - Commitment to a robust dividend policy and significant stock buybacks, with approximately HKD 340 million spent on repurchases since 2025 [23] - **Competitive Advantage**: - Strong background in TCM from China provides a competitive edge in international markets [6][19] - **Challenges in International Markets**: - Variability in local regulations for TCM practitioners, necessitating a dual approach of local hiring and sending qualified Chinese practitioners abroad [20][21] This summary encapsulates the key points from the conference call, highlighting Guoshengtang's strategic initiatives, financial performance, and market outlook.

Group 1 - The latest shareholder equity disclosures were made by Lu Group (Vietnam), Superman Intelligence, Tianjie Environment, and Gushengtang on November 18, 2025 [1] Group 2 - Lu Group (Vietnam) maintained its shareholding at 274 million shares, representing 54.62% ownership, slightly up from 54.60% previously [2] - Tai Dong Holding Limited acquired 62.5 million shares in Superman Intelligence, resulting in an 8.74% ownership, up from 0% [2] - Tianjie Environment saw multiple shareholders increase their holdings, with Zheji City Keyuan Enterprise increasing from 40.50% to 43.20%, and other shareholders like Bian Yu and Bian Shu also increasing their stakes to 50.89% and 45.94% respectively [2] - Gushengtang's shareholder Tu Zhiliang increased his holdings from 81.0036 million shares to 81.2736 million shares, raising his ownership from 34.98% to 35.10% [2]